2012-06-19T17:06:58-04:00 2011-09-30 GRANT THORNTON LLP 666 THIRD AVENUE NEW YORK NY 100174011 990 2010-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH FOUN 2128061600 120 wall street 13TH FLOOR NEW YORK NY 100053908 Bradley Jensen 2012-06-19 2125990100 2010 2016-02-24 21:20:13Z amfar KEVIN FROST 120 WALL STREET 13TH FLOOR new york NY 10005 44969834 false X WWW.AMFAR.ORG X 1983 NY amfar is dedicated to ending the global aids epidemic through innovative research. 19 19 84 145 0 0 21965059 31689016 0 0 506704 885610 2889638 -5259666 25361401 27314960 4604199 6694401 0 0 7735764 8447012 483987 403813 4438779 10930086 10565187 23754036 26110413 1607365 1204547 35804430 38004315 5238664 6564234 30565766 31440081 X The Foundation for AIDS Research is an international not-for-profit organization incorporated in New York in 1989. amfAR was formed through the unification in 1985 of two not-for-profit organizations, the AIDS Medical Foundation ("AMF"), incorporated in New York in April 1983, and the National AIDS Research Foundation, incorporated in California in August 1985. First based in California, amfAR transferred its legal domicile to New York in 1989, using the initial incorporation documents of AMF, making it AMF's legal successor. amfAR has offices in New York, NY, Washington, D.C., and Bangkok, Thailand. On March 7, 2005, the board of trustees of the American Foundation for AIDS Research approved a change in legal name to "The Foundation for AIDS Research." On October 18, 2005, the New York State Department of State approved this change. In addition, the Foundation has secured approval for Doing Business As (DBA) the following: - American Foundation for AIDS Research - amfAR - AIDS Researc false false 7511991 3125468 0 RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o. 5915106 2561037 0 TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2011. For further details, see Schedule o. 2800605 0 0 EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. For further details, see Schedule O. 1851360 852896 0 MSM Initiative 1616906 155000 0 public policy 3468266 1007896 0 19695968 true true false true false false true false true true false false false true true true false false true true true false true true false false true false true false false false false false false false false true false false false false false false false false false true 83 0 true 84 true false true TH false false false true true false false false false X 19 19 false false false false false false false true true false false true true true true true true true true false AL AK AZ AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WV WI X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR new york NY 100053908 Dame Elizabeth Taylorthru 311 1.0 X X 0 0 0 Mathilde Krim PhD 1.0 X X 0 0 0 Kenneth Cole 1.0 X X 0 0 0 Patricia J Matson 1.0 X X 0 0 0 John C Simons 1.0 X X 0 0 0 Wallace Sheft CPA 1.0 X X 0 0 0 Mervyn F Silverman MDMPH 1.0 X X 0 0 0 Arlen H Andelson 1.0 X 0 0 0 Harry Belafonte 1.0 X 0 0 0 David Bohnett 1.0 X 0 0 0 Zev Braun 1.0 X 0 0 0 Jonathan S Canno 1.0 X 0 0 0 Donald Capoccia 1.0 X 0 0 0 R Martin Chavez PhD 1.0 X 0 0 0 Jane B Eisner 1.0 X 0 0 0 T Ryan Greenawalt 1.0 X 0 0 0 Regan Hofmann 1.0 X 0 0 0 Michael J Klingensmith 1.0 X 0 0 0 Michele V McNeill PharmD 1.0 X 0 0 0 Richard H Metzner 1.0 X 0 0 0 Edward Milstein 1.0 X 0 0 0 Cindy Rachofsky 1.0 X 0 0 0 Vincent A Roberti 1.0 X 0 0 0 Bill Roedy 1.0 X 0 0 0 Alan D Schwartz 1.0 X 0 0 0 Diana L Taylor 1.0 X 0 0 0 Kevin Wendle 1.0 X 0 0 0 Kevin Frost 40.0 X 343450 0 44502 Bradley Jensen 40.0 X 191604 0 39664 John F Logan JD PhD 40.0 X 179618 0 21376 Rowena Johnston 40.0 X 145204 0 18490 Edward Donnelly 40.0 X 135171 0 14779 Gregory L Boroff 40.0 X 207364 0 23175 Christopher Collins 40.0 X 165536 0 36334 Annette Sohn 40.0 X 172673 0 15849 Eric Muscatell 40.0 X 146674 0 18680 Andrew McInnes 40.0 X 123252 0 34404 Anthony Ancona 40.0 X 143131 0 10241 Susan Doster 40.0 X 127277 0 16423 AnnMarie Shannahan 40.0 X 122379 0 6022 2203333 0 299939 16 false true false aab production 64 allen street 5th floor NEW YORK NY 10002 events production 243200 grant thornton llp 1901 w meyers road suite 455 OAKBROOK TERRACE IL 60181 accounting & audit 152288 downey mcgrath group inc 27 west 24th street suite 900 NEW YORK NY 10010 program tech support 127500 Global Health Institute 3403 rolling court CHEVY CHASE MD 20815 consulting 120000 john mini consulting inc 707 savannah road LEWES DE 19958 direct mail 116350 8 388831 17594927 5432260 8272998 262516 31689016 0 737166 737166 0 214797 214797 10593526 10445082 148444 148444 148444 1452830 17594927 7203604 -5750774 -5750774 0 242362 6188 236174 236174 LIST RENTALS 900099 26881 26881 MISCELLANEOUS INCOME 900099 13256 13256 40137 27314960 0 -4374056 2510544 2510544 0 4183857 4183857 0 2390379 1607250 280435 502694 0 4760549 3528307 233963 998279 177016 42792 91249 42975 702348 275602 266808 159938 416720 181953 121905 112862 0 61465 56102 5363 204790 204790 62250 62250 403813 403813 123027 123027 1390134 819672 61904 508558 54170 43460 149 10561 86473 53779 9844 22850 36774 25194 5126 6454 0 1186330 810213 164857 211260 803002 492998 9977 300027 0 976913 852029 14522 110362 0 0 250337 171695 34935 43707 161705 110784 22542 28379 PROGRAM MATERIALS 2179167 2179167 0 0 POSTAGE & SHIPPING 668406 284033 2725 381648 PROGRAM TECHNICAL SUPPORT 591246 591246 0 0 PRINTING 563260 215138 0 348122 BAD DEBT EXPENSE 262348 179723 36586 46039 903390 418180 284959 200251 26110413 19695968 1975666 4438779 X 1018136 335788 682348 5446802 6837885 5963522 216839 6860128 5793558 2471863 2949128 144295 94865 513604 418292 3305513 2756566 471557 548947 13623286 20785048 309373 359753 35804430 38004315 1644227 1894675 573765 1394222 2679898 3003684 340774 271653 5238664 6564234 X 18976216 20620662 11262381 10486272 327169 333147 30565766 31440081 35804430 38004315 X 1204547 -330232 X false true true X true true X 22038265 30491706 20760601 22553697 22876129 118720398 22038265 30491706 20760601 22553697 22876129 118720398 5841089 112879309 822092 842799 643473 668573 951963 3928900 20042 4177745 117005 2317760 1492968 8125520 130774818 203937 0.86316 0.84905 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false false false true 138471 138471 false false Lobbying Expenses Part II-B The Foundation for AIDS Research developed issue briefs on the potential impact of various budget scenarios for global health, new approaches to HIV prevention among gay men, the policy implications of scientific advances in AIDS, and other issues. These issue briefs were shared with Capitol Hill staff. AMFAR met regularly with staff to members of Congress and with Administration staff. AMFAR held briefings on Capitol Hill on how to "End the Epidemic," HIV prevention, and AIDS research. amfAR uses these briefings as an educational tool. AMFAR contracted with a consultant to encourage advocacy by constituents in key states on global AIDS funding. 94865 X Donated Items, Inventory etc. true 561083 5978 -2705 100000 464356 516826 8258 35999 561083 470065 9378 37383 516826 0.28260 0.71740 false false 781297 743877 37420 236509 233430 3079 2287707 1779259 508448 548947 0 MISCELLANEOUS 271653 271653 27314960 26110413 1204547 -465956 135728 -330228 874319 27165227 -465956 316223 -149733 27314960 27314960 26290908 180495 180495 26110413 26110413 Endowments Part V, Line 4 AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors. FIN 48 Income taxes Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2011, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2008, 2009, and 2010 are still open to audit for both federal and state purposes. reconciliation part XI, Line 8 Value of Donated Services Capitalized Rather than Expenses - $135,728 (Please refer to Part XII, Line 2(b) and Part XIII, Line 2(a) for the difference in the reported amount of donated services). Collections of Art, Histocial Treasures, or other similar assets Part III, Line 4 AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them. true Central America and the Caribbean 0 0 Grantmaking N/A 399614 East Asia and the Pacific 1 15 Program Services Therapeutics Research 1249297 East Asia and the Pacific 1 15 Grantmaking N/A 2759765 Europe (Including Iceland and Greenland) 0 0 Grantmaking N/A 466145 Europe (Including Iceland and Greenland) 0 0 Fundraising N/A 3032080 North America 0 0 Fundraising N/A 272343 Russia and the Newly Independent States 0 0 Grantmaking N/A 132018 South America 0 0 Fundraising N/A 437282 South Asia 0 0 Grantmaking N/A 93360 Sub-Saharan Africa 0 0 Grantmaking N/A 184202 Middle East and North Africa 0 0 Grantmaking N/A 19789 South America 0 0 Grantmaking N/A 128964 2 30 2 30 9174859 9174859 Cent. America/Caribbean MSM INITIATIVES 20000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 20000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 20000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 19636 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 19978 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 10000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 10000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 20000 Wire Transfe Cent. America/Caribbean MSM INITIATIVES 10000 Wire Transfe Cent. America/Caribbean PREVENTION SCIENCE OUTREACH 250000 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 12375 Wire Transfe East Asia/Pacific TREAT ASIA 7501 Wire Transfe East Asia/Pacific TREAT ASIA 5710 Wire Transfe East Asia/Pacific BASIC RESEARCH 46875 Wire Transfe East Asia/Pacific BASIC RESEARCH 36456 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 50000 Wire Transfe East Asia/Pacific TREAT ASIA 20000 Wire Transfe East Asia/Pacific TREAT ASIA 12746 Wire Transfe East Asia/Pacific TREAT ASIA 21825 Wire Transfe East Asia/Pacific TREAT ASIA 12080 Wire Transfe East Asia/Pacific TREAT ASIA 15724 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 10874 Wire Transfe East Asia/Pacific TREAT ASIA 28954 Wire Transfe East Asia/Pacific TREAT ASIA 15724 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 11626 Wire Transfe East Asia/Pacific TREAT ASIA 52083 Wire Transfe East Asia/Pacific TREAT ASIA 329578 Wire Transfe East Asia/Pacific TREAT ASIA 159548 Wire Transfe East Asia/Pacific TREAT ASIA 143428 Wire Transfe East Asia/Pacific TREAT ASIA 31893 Wire Transfe East Asia/Pacific TREAT ASIA 14316 Wire Transfe East Asia/Pacific TREAT ASIA 100000 Wire Transfe East Asia/Pacific TREAT ASIA 116501 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 14589 Wire Transfe East Asia/Pacific TREAT ASIA 14999 Wire Transfe East Asia/Pacific TREAT ASIA 37499 Wire Transfe East Asia/Pacific TREAT ASIA 9000 Wire Transfe East Asia/Pacific TREAT ASIA 11250 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 7500 Wire Transfe East Asia/Pacific TREAT ASIA 6000 Wire Transfe East Asia/Pacific TREAT ASIA 16350 Wire Transfe East Asia/Pacific TREAT ASIA 14999 Wire Transfe East Asia/Pacific TREAT ASIA 24374 Wire Transfe East Asia/Pacific TREAT ASIA 16350 Wire Transfe East Asia/Pacific TREAT ASIA 21375 Wire Transfe East Asia/Pacific TREAT ASIA 8400 Wire Transfe East Asia/Pacific TREAT ASIA 14950 Wire Transfe East Asia/Pacific TREAT ASIA 5625 Wire Transfe East Asia/Pacific TREAT ASIA 33054 Wire Transfe East Asia/Pacific TREAT ASIA 7500 Wire Transfe East Asia/Pacific TREAT ASIA 5625 Wire Transfe East Asia/Pacific TREAT ASIA 10000 Wire Transfe East Asia/Pacific TREAT ASIA 12080 Wire Transfe East Asia/Pacific TREAT ASIA 5625 Wire Transfe East Asia/Pacific TREAT ASIA 16126 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 11250 Wire Transfe East Asia/Pacific TREAT ASIA 7333 Wire Transfe East Asia/Pacific TREAT ASIA 5550 Wire Transfe East Asia/Pacific TREAT ASIA 7500 Wire Transfe East Asia/Pacific TREAT ASIA 5625 Wire Transfe East Asia/Pacific TREAT ASIA 9398 Wire Transfe East Asia/Pacific TREAT ASIA 7125 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 26430 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 6375 Wire Transfe East Asia/Pacific TREAT ASIA 11250 Wire Transfe East Asia/Pacific TREAT ASIA 7501 Wire Transfe East Asia/Pacific TREAT ASIA 5271 Wire Transfe East Asia/Pacific TREAT ASIA 14625 Wire Transfe East Asia/Pacific TREAT ASIA 7200 Wire Transfe East Asia/Pacific TREAT ASIA 16350 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 20626 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 34138 Wire Transfe East Asia/Pacific TREAT ASIA 30000 Wire Transfe East Asia/Pacific TREAT ASIA 6300 Wire Transfe East Asia/Pacific TREAT ASIA 6525 Wire Transfe East Asia/Pacific TREAT ASIA 10000 Wire Transfe East Asia/Pacific TREAT ASIA 20550 Wire Transfe East Asia/Pacific TREAT ASIA 20626 Wire Transfe East Asia/Pacific TREAT ASIA 21800 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 11250 Wire Transfe East Asia/Pacific TREAT ASIA 92000 Wire Transfe East Asia/Pacific TREAT ASIA 7501 Wire Transfe East Asia/Pacific TREAT ASIA 20000 Wire Transfe East Asia/Pacific TREAT ASIA 131202 Wire Transfe East Asia/Pacific TREAT ASIA 60992 Wire Transfe East Asia/Pacific TREAT ASIA 5900 Wire Transfe East Asia/Pacific TREAT ASIA 11626 Wire Transfe East Asia/Pacific TREAT ASIA 10103 Wire Transfe East Asia/Pacific TREAT ASIA 27195 Wire Transfe East Asia/Pacific MSM INITIATIVE 19900 Wire Transfe East Asia/Pacific TREAT ASIA 38715 Wire Transfe East Asia/Pacific TREAT ASIA 43482 Wire Transfe East Asia/Pacific TREAT ASIA 6000 Wire Transfe East Asia/Pacific MSM INITIATIVE 20000 Wire Transfe East Asia/Pacific MSM INITIATIVE 20000 Wire Transfe East Asia/Pacific MSM INITIATIVE 19963 Wire Transfe East Asia/Pacific MSM INITIATIVE 16700 Wire Transfe East Asia/Pacific MSM INITIATIVE 20000 Wire Transfe East Asia/Pacific MSM INITIATIVE 18600 Wire Transfe East Asia/Pacific MSM INITIATIVE 15000 Wire Transfe East Asia/Pacific MSM INITIATIVE 19700 Wire Transfe East Asia/Pacific TREAT ASIA 15000 Wire Transfe East Asia/Pacific TREAT ASIA 19950 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 5223 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 15626 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 70000 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 26640 Wire Transfe Europe/Iceland/Greenland MSM INITIATIVE 18000 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 210000 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 36456 Wire Transfe Europe/Iceland/Greenland BASIC RESEARCH 90000 Wire Transfe Middle East/North Africa MSM INITIATIVE 19789 Wire Transfe Russia MSM INITIATIVE 20000 Wire Transfe Russia MSM INITIATIVE 18000 Wire Transfe Russia MSM INITIATIVE 19891 Wire Transfe Russia MSM INITIATIVE 9500 Wire Transfe Russia MSM INITIATIVE 10364 Wire Transfe Russia MSM INITIATIVE 19861 Wire Transfe Russia MSM INITIATIVE 16680 Wire Transfe Russia MSM INITIATIVE 17722 Wire Transfe South America MSM INITIATIVE 19790 Wire Transfe South America MSM INITIATIVE 20000 Wire Transfe South America MSM INITIATIVE 19975 Wire Transfe South America MSM INITIATIVE 19976 Wire Transfe South America MSM INITIATIVE 20000 Wire Transfe South America MSM INITIATIVE 19260 Wire Transfe South America MSM INITIATIVE 9963 Wire Transfe South Asia treat asia 15000 Wire Transfe South Asia treat asia 15000 Wire Transfe South Asia treat asia 5625 Wire Transfe South Asia treat asia 8662 Wire Transfe South Asia MSM INITIATIVE 20000 Wire Transfe South Asia MSM INITIATIVE 19148 Wire Transfe Sub-Saharan Africa BASIC RESEARCH 14264 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa PUBLIC POLICY 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 10000 Wire Transfe Sub-Saharan Africa PUBLIC POLICY 20000 Wire Transfe Sub-Saharan Africa MSM INITIATIVE 20000 Wire Transfe 157 0 false false false false false false Foreign Activities Part I, Line 2 International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period. foreign activities Part I, Line 3, Column D The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives. Foreign Activities - Status of Grantees The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 157 charities supported are presumed to be the equivalent of U.S. charities. X X X X X X true aab productions Fundraising Event/Prod false 11113567 222400 10891167 john mini consulting inc direct mail false 2108612 120500 1988112 public interest communications tele marketing false 38269 51679 -13410 sgr consulting event production false 333385 70500 262885 telefund tele marketing false 142199 85634 56565 13736032 550713 13185319 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MI MN MS MO MT NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VA WA WV WI CANNES EVENT 8886797 8474297 412500 544532 1834820 DALLAS EVENT 4223695 4132495 91200 46803 2334363 10 5937265 4988135 949130 151155 2291931 19047757 17594927 1452830 742490 6461114 7203604 -5750774 Schedule G, Part I The Foundation for AIDS Research actually paid out $403,803 in fundraising expenses for the year ending September 30, 2011. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $550,713. Of that $550,713, only $403,813 was paid for fundraising services, the remaining $146,900 was paid for event production services. true University of Utah 75 S 2000 E Second Fl Salt Lake City UT 84112 187600525 501(c)(3) 15626 basic research Dana-Farber Cancer Institute Harvard Medical Sch 44 Binney St Boston MA 02115 042263040 501(c)(3) 15626 Basic Research University of Utah 75 S 2000 E Second Fl Salt Lake City UT 84112 187600525 501(c)(3) 31251 Basic Research Yale University School of Medicine 47 College Street New Haven CT 06520 060646973 501(c)(3) 15626 Basic Research Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10065 131623978 501(c)(3) 62502 Basic Research UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 753909105 175600286 501(c)(3) 62502 Basic Research NYU School of Medicine 550 First Avenue New York NY 10016 113556230 501(c)(3) 36460 Basic Research University of California-Davis One Shields Avenue Davis CA 95616 946036494 501(c)(3) 62501 Basic Research California Institute of Technology 1200 East California Blvd Pasadena CA 91106 951643307 501(c)(3) 62501 Biomedical Cure Research University of Minnesota 200 Oak Street SE Minneapolis MN 554552070 416007513 501(c)(3) 62501 Basic Research University of Florida 1600 SW Archer Rd ARB R1-252 Gainesville FL 32610 592729133 501(c)(3) 50000 Basic Research University of WashingtonFHCRC 1100 Fairview Avenue N D3-100 Seattle WA 98109 916001537 501(c)(3) 40000 Basic Research University of Texas Southwestern 5323 Harry Hines Blvd L4256 Dallas TX 75390 175600286 501(c)(3) 20000 Basic Research Albert Einstein College of Medicine 1300 Morris Park Avenue Bronx NY 10461 132937352 501(c)(3) 33333 Basic Research The Regents of the Univ of California SF 333 California Street Suite 315 San Francisco CA 94110 946036493 501(c)(3) 210000 Basic Research Johns Hopkins University 733 N Broadway 117 Broadway Res Baltimore MD 21205 520595110 501(c)(3) 210000 Biomedical Cure Research Beckman Research Institue of City of Hope 1500 E Duarte Road Duarte CA 910103000 953432210 501(c)(3) 70000 Biomedical Cure Research NYU School of Medicine 550 First Avenue New York NY 10016 113556230 501(c)(3) 21999 Social/Behavioral Research Montefiore Medical Center 111 E 210th St Bronx NY 10467 131740114 501(c)(3) 22000 Policy Research Dana-Farber Cancer Institute Inc 44 Binney St Boston MA 02115 042263040 501(c)(3) 46875 Basic Research University of Wisconsin-Madison 21 North Park Street Suite 6401 Madison WI 53715 396006492 501(c)(3) 46875 Basic Research The Aaron Diamond AIDS Research Center 455 First Avenue 7th Floor New York NY 10016 133540234 501(c)(3) 46875 Basic Research VGTI-Florida 11350 SW Village Parkway Port St Lucie FL 34987 364618350 501(c)(3) 70000 Biomedical Cure Research University of California Los Angeles 11000 Kinross Avenue Suite 102 Los Angeles CA 900951406 956006143 501(c)(3) 70000 Basic Research University of Utah 15 North Medical Dr East 2100 25 Salt lake City UT 84112 876000525 501(c)(3) 69972 Basic Research University of Alabama at Birmingham 1530 Third Avenue South AB 1170 Birmingham AL 352940111 163600539 501(c)(3) 50000 Biomedical Cure Research George Mason University 10900 Univ Blvd Discovery Hall Ro Manassas VA 20110 540836354 501(c)(3) 58460 Basic Research William J Clinton Foundation 1200 President Clinton Avenue Little Rock AR 72201 311580204 501(c)(3) 111000 Operations support for HIV/AIDS programs Stanford University 301 Ravenswood Avenue Menlo Park CA 94025 941156365 501(c)(3) 96782 Basic Research William J Clinton Foundation 1200 President Clinton Avenue Little Rock AR 72201 311580204 501(c)(3) 67339 Operations support for HIV/AIDS programs Heartland Alliance for Human Needs and Rights 208 South LaSalle Street Suite 181 Chicago IL 60604 361877640 501(c)(3) 10500 Direct Service/intervention William J Clinton Foundation 1200 President Clinton Avenue Little Rock AR 77201 311580204 501(c)(3) 75000 Operations support for HIV/AIDS programs Beth Israel Medical Center - Edmond de Rothschild First Avenue at 18th Street New York NY 10003 135564934 501(c)(3) 75000 Policy Research Johns Hopkins University 733 N Broadway Baltimore MD 21205 520595110 501(c)(3) 55999 Biomedical Cure Research University of California San Francisco 333 California Street Suite 315 San Francisco CA 94118 946036493 501(c)(3) 90000 Biomedical Cure Research Trustees of the University of Pennsylvania 3451 Walnut Street Room P 221 Philadelphia PA 19104 231352685 501(c)(3) 40000 Biomedical Cure Research Johns Hopkins University 733 N Broadway 117 Broadway Res Baltimore MD 21205 520595110 501(c)(3) 90000 Biomedical Cure Research Project Inform 1375 Mission Street San Francisco CA 94103 943052723 501(c)(3) 10000 Research/Conference Support Case Western Reserve University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 39600 Biomedical Cure Research Johns Hopkins University Room 117 Broadway Research Buildin Baltimore MD 21205 520595110 501(c)(3) 319147 Biomedical Cure Research Johns Hopkins University Bloomberg School of Publi 615 N Wolfe Street Baltimore MD 21205 520595110 501(c)(3) 75000 Policy Research 41 0 Grants and Assistance Part I, Line 2 All U.S. 501(c)(3) grant and award recipients are required to report at least once on activities supported with amfAR funds; all U.S. research grant recipients (which include 501(c)(3) organizations and other nonprofit entities such as state universities) are required to submit an interim and a final progress report in addition to expenditure reports due following the ends of the 2nd, 3rd and final quarters of the performance periods. Reports are reviewed by grant administration and program staff prior to payment and/or closeout. X X X X X true true false false false false false false false Kevin Frost 343450 0 0 0 0 0 27150 0 17352 0 387952 0 0 0 Bradley Jensen 191604 0 0 0 0 0 14303 0 25361 0 231268 0 0 0 John F Logan JD PhD 179618 0 0 0 0 0 13122 0 8254 0 200994 0 0 0 Rowena Johnston 145204 0 0 0 0 0 10236 0 8254 0 163694 0 0 0 Gregory L Boroff 207364 0 0 0 0 0 14921 0 8254 0 230539 0 0 0 Christopher Collins 165536 0 0 0 0 0 10973 0 25361 0 201870 0 0 0 Annette Sohn 172673 0 0 0 0 0 12078 0 3771 0 188522 0 0 0 Eric Muscatell 146674 0 0 0 0 0 10426 0 8254 0 165354 0 0 0 Andrew McInnes 123252 0 0 0 0 0 9043 0 25361 0 157656 0 0 0 Anthony Ancona 143131 0 0 0 0 0 10110 0 131 0 153372 0 0 0 Compensation Part I, Line 4 Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2010. X 11 18387 sales price X Computers 1 135727 Fair Market Value X Airline Tickets 1 108402 Fair Market Value false false true Form 990, Schedule M, line 32a To the extent that the organization receives contributions of securities, it uses its investment broker to liquidate those holdings to fund amfar's various research program activities. Program Service Accomplishments(1) Part III, Line 4a-4d(1) Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2011, amfAR awarded 22 new grants and fellowships totaling $3,040,608. Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2011 Krim Fellows-each of whom received $125,000-are working on new ways to treat HIV/AIDS and its associated conditions, as well as an HIV vaccine. Among the 2011 fellows is Nicholas Maness, Ph.D., of the University of Wisconsin-Madison, whose aim is to discover new proteins to act as targets for an HIV vaccine. All of the standard methods for making a vaccine, and even new ones not previously tried for any other disease; have so far failed to generate a product that can reduce the risk of HIV infection. Vaccines normally work by inducing immune responses against proteins associated with the virus they are intended to block. Dr. Maness believes there are previously undiscovered HIV proteins, and that the virus also makes proteins in a backwards (technically known as antisense) orientation. He will test for the presence and function of such novel HIV proteins to determine whether they may serve as the basis for a vaccine. Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010. Building on momentum from its first round of cure-focused grants issued last year, amfAR announced a second round of grants in 2011 to enable some teams to continue their groundbreaking research while adding two additional, promising projects aimed at unlocking more information about how to potentially eradicate HIV infection. Program Service Accomplishments(2) Part III, Line 4a-4d (2) Line 4a, Continued - The second round of funding, totaling $1,042,000 went to five collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. Dr. Adriana Andrade of Johns Hopkins University, new to the ARCHE consortium, is testing the ability of disulfiram-a drug approved by the US Food and Drug Administration to treat alcoholism-to drive the virus out of infected cells in a small clinical study. Dr. Bob Siliciano, during his first year of ARCHE funding, identified and characterized the drug as an agent that might flush virus out of latently HIV-infected cells. Collaborating with Dr. Janice Clements, also of Johns Hopkins, he is investigating other FDA-approved drugs for their effect on latent HIV during his second year of funding. Also among this year's ARCHE grantees, Dr. Mike McCune of the University of California, San Francisco, collaborating with Dr. Steven Deeks, is examining the role of ongoing activation of the immune system-long suspected of playing a role in HIV disease-in the ability of HIV to persist during the lifetime of an infected patient. They will also test an FDA-approved drug that could play an integral role in a potential new therapeutic strategy that could bring us closer to a functional cure. Collaborating with the ARCHE investigators at UCSF, including Drs. Steven Deeks and Frederick Hecht, second-time ARCHE grantee Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control and Karolinska Institute continues to investigate which cellular reservoirs are most responsible for the persistence of HIV. These findings will inform efforts by the Siliciano/Clements and McCune/Deeks ARCHE groups by identifying the important targets of their efforts to purge reservoirs of virus or to modulate immune activation to effect a cure. The other new ARCHE grantee, Dr. Una O'Doherty of the University of Pennsylvania, is comparing methods for measuring HIV reservoir size to determine which are the most accurate and practical. The persistent reservoir of virus constitutes a tiny fraction of all virus present, but understanding how to measure changing levels of virus in the reservoir is difficult-and crucial to determining the next steps in HIV eradication. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 34 scientific publications resulted from amfAR-funded research. These covered current and past targeted areas of research interest. In the Lab, Recreating HIV's Hidden Reservoirs One major obstacle to curing HIV is the persistence in tissues of latent virus that is resistant to attack by current antiretroviral therapy (ART). Recent studies-including several published by amfAR grantees-have documented encouraging progress in the search for the reservoirs where virus persists. But even after zeroing in on HIV's hiding places, scientists need simple, clinically relevant test-tube models for testing new means of attacking the virus in these reservoirs. Dr. Alberto Bosque, one of amfAR's 2009 Mathilde Krim Fellows in Basic Biomedical Research, has helped to develop one such system. Writing in the January issue of the research journal Methods, Bosque and his mentor, Dr. Vicente Planelles, of the University of Utah, reviewed problems with older models of HIV latency. The authors concluded that no single test-tube or animal model for HIV latency is likely to capture the broad spectrum of means by which HIV hides or becomes activated. But their new system brings us one step closer to defining critical factors involved in maintaining latent HIV, with the ultimate aim of rationally designing drugs to destroy such viruses. An Animal Model for a Functional Cure for AIDS Writing in the August issue of PLoS Pathogens, a prestigious online journal, amfAR grantee Dr. Cristian Apetrei and colleagues described a functional cure of SIV, the simian counterpart of HIV, in rhesus monkeys. A functional cure controls the virus at extremely low levels in the body while a sterilizing cure entirely eliminates the virus from the body. Several critical pieces of the HIV disease puzzle have been addressed by their study. First, it shows that the immune system, through the CD8+ "killer" T cell, contributes to the control of an HIV-like infection. Second, it suggests that the chronic immune activation characteristic of HIV infection, even in those patients whose virus is seemingly well-controlled with drugs, is the result of incomplete suppression of virus. And unless such low levels of continuous virus growth can be blocked, it may preclude restoration of normal immunity. As Apetrei and associates appropriately concluded, their model provides the opportunity for further investigation into the phenomenon of "super-elites," which should enable "design of new approaches for controlling HIV infection" and help make a functional cure a reality. The Ethics of Universal HIV Screening Seeking to encourage earlier and more widespread HIV testing, in 2006 the U.S. Centers for Disease Control and Prevention (CDC) recommended an "opt-out" approach to testing, whereby healthcare workers would inform patients that they would be tested unless they declined. The aim of the new guidelines was to expand the number of HIV infections being diagnosed-considered a key to slowing the spread of the virus-and to get people into treatment earlier, thereby reducing the level of virus in their bodies and rendering them less infectious to others. Yet few national professional organizations have endorsed this recommendation. amfAR-supported researcher Dr. Roland Merchant of Brown University, writing in the American Journal of Bioethics, addresses the ethical concerns surrounding such testing. Merchant and colleagues concluded that if properly implemented, the CDC recommendations on universal testing could benefit both individuals and society. They emphasized that patients must be informed clearly that testing will take place, provided with informational materials about HIV and HIV testing, and told that they have the right to refuse testing. If the new HIV testing recommendations are otherwise ethically acceptable, their adoption should require only these sorts of safeguards to assure they are properly implemented. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2011 for biomedical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication. Think Tanks and Conferences In April 2011, amfAR co-sponsored a think tank in Baltimore that brought together more than 50 leading academic researchers, government scientists, regulators, and community advocates to identify steps that can be taken to hasten the progress of cure-related research. And in July, amfAR Vice President and Director of Research Dr. Rowena Johnston co-chaired-with Nobel Prize winning scientist Dr. Franoise Barr-Sinoussi-"Controversies in HIV Cure Research," a panel discussion held in conjunction with the International AIDS Society conference in Rome. Program Service Accomplishments (3) Part III, Line 4a-4d (3) Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2011. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 5,500 patients at 22 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult TAHOD program, and includes data from approximately 4,000 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. To support IeDEA, TREAT Asia is contributing anonymous data from approximately 13,600 patients at 60 clinical centers in 13 countries within Asia and Australia. Investing in Adolescent Research TREAT Asia is currently supporting three studies that it hopes will inform and improve adolescent HIV treatment and care in Southeast Asia. This first is examining the incidence of human papillomavirus (HPV) infection?a precursor to cervical and anal cancer?in HIV-positive adolescents. A second study is assessing bone mineral density levels in children living with HIV and finding preliminary correlations between the use of antiretroviral therapy and bone density loss. The third study is using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Reaching Out to MSM In 2011, TREAT Asia became a proud co-sponsor of www.adamslove.org, a new non-commercial website providing HIV/AIDS information to men who have sex with men (MSM) in Thailand. An initiative of the Thai Red Cross AIDS Research Centre, Adam's Love innovatively combines education and entertainment, and is the first website of its kind in Southeast Asia. The website's creative team has partnered with amfAR to explore initiating a similar "edutainment" website in Indonesia. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. With funding from IeDEA, in 2009 TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized 13 workshops and training sessions in 2011 including sessions on basic research skills (e.g., ethics, biosafety, research methods), laboratory training (e.g., HIV drug resistance testing), and clinical management of HIV (e.g., cancer, treatment failure, care of MSM). Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community friendly" educational brochures on HIV treatment standards in local languages. TREAT Asia also continues its partnership with UNAIDS, the Asia-Pacific Network of People Living with HIV/AIDS, the International Treatment Preparedness Coalition, and the Mdecins Sans Frontires Access Campaign. Through the Asia Treatment Working Group, TREAT Asia is part of a platform for promoting treatment access and higher quality HIV healthcare within the region. In 2011, TREAT Asia continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. XVIII International AIDS Conference TREAT Asia was well represented at the International AIDS Society Conference in July 2011 in Rome, Italy, where several network members and partners presented their research findings. In addition, TREAT Asia was a scientific co-sponsor of the 3rd International Workshop on HIV Pediatrics, which preceded the conference. 14th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2011 and was organized by HIV-NAT, a TREAT Asia network site. Program Service Accomplishments (4) Part III, Line 4a-4d (4) Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. amfAR25 amfAR commemorated 25 years of operation in 2011 and marked the occasion with a range of events and activities. The Foundation adopted the tagline "Making AIDS History" for the year and incorporated it into a special commemorative logo. Three short films were produced to commemorate the anniversary. One of them, narrated by amfAR Global Fundraising Chairman Sharon Stone, traced amfAR's history and showcased the Foundation's achievements. The other two were narrated by Vanessa Redgrave and paid tribute to the Foundation's founders - Dr. Mathilde Krim and Dame Elizabeth Taylor. Ironically, and tragically, Dame Elizabeth passed away in March of 2011. A special website - www.makingaidshistory.org - was created to capture the personal stories of a diverse group of people living with HIV from different backgrounds and different parts of the country. The site and the stories stimulated media interest and coverage of the individuals in local outlets in several parts of the country. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of a people and a generally younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page, mounted a campaign to increase Facebook followers, and live tweeted from fundraising and program events. It also expanded its YouTube channel content with a range of educational videos. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, the Washington Post, New York magazine, Reuters, Bloomberg News, and The Huffington Post. amfAR's leadership role in AIDS research was highlighted in late November 2010, when the iPrEx study results were released and outlets including The New York Times, The Wall Street Journal, the Financial Times, Agence-France Presse, and PBS NewsHour relied on amfAR CEO Kevin Frost or Vice President and Director of Public Policy for Chris Collins for commentary on what the results meant for the future of HIV/AIDS prevention and research. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2011, celebrity supporters included amfAR Ambassadors Cheyenne Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Janet Jackson, Kylie Minogue, Dita Von Teese, Heidi Klum, Alan Cumming, Stevie Wonder, Gladys Knight, Dionne Warwick, Elton John, Richard Gere, Rosie O'Donnell, Whoopi Goldberg, Jennifer Hudson, John Legend, Andy Cohen, Diane Kruger, Kathy Griffin, Kim Cattrall, Stanley Tucci, and Rufus Wainwright. Program Service Accomplishments (5) Part III, Line 4a-4d (5) THE MSM INITIATIVE: amfAR's MSM Initiative was launched in 2007 to respond to the alarmingly high rates of HIV among MSM, a group that in low- and middle-income countries is on average 19 times more likely to be infected than the general population. Stigma, discrimination, and legal prohibitions have fueled the spread of the epidemic among MSM, most of whom do not have access to HIV prevention, treatment, and care services. The MSM Initiative aims to reduce the spread and impact of HIV infection among MSM in resource-limited countries by providing support to grassroots groups through its community awards program. The program also works to raise awareness of HIV among MSM and to advocate increased funding for MSM-targeted services. Community Awards In 2011, amfAR awarded more than $775,000 to 44 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Africa amfAR awarded funding to eight groups in Africa: Humanity First Cameroon and Alternatives-Cameroun; an unnamed group in Ethiopia (name withheld by request); PEMA Kenya; Stop AIDS In Liberia; Association de lutte contre le sida (Morocco); Gender DynamiX (South Africa); and Gays and Lesbians of Zimbabwe. PEMA Kenya (Mombasa, Kenya) Building upon a previous amfAR award, PEMA Kenya is addressing stigma, discrimination, and criminalization of MSM and LGBT individuals among the religious community and media and law enforcement professionals in coastal Kenya. Emphasis is placed on the implications of stigma in accessing HIV prevention and treatment and other health services. Asia-Pacific Eleven organizations in Asia and the Pacific received community awards in two separate rounds of awards: Loving Support Center for Health and Education and another unnamed group in China; AIDS Task Force of Fiji; Sangama (India); Youth for Health Center (Mongolia); TLF Sexuality, Health and Rights Educators Collective, Incorporated (Philippines); The Human Rights Education Institute of Burma (Thailand); Beijing Ark of Love PLWHA Supporting Group (China); PT Foundation (Malaysia); AIDS Awareness Society (Pakistan); and Vietnamese Community Mobilisation Center for HIV/AIDS Control (Vietnam). Loving Support Center for Health and Education (China) This direct service intervention is promoting the health and rights of male sex workers in Shenyang and Tianjin. Employing a rights-based approach, the project empowers sex workers to assist and support each other, builds skills for health and well-being, and provides STI/HIV information and referrals. The project is also producing the first-ever male sex worker periodical in China. Caribbean Nine grassroots organizations in the Caribbean received amfAR funding: United Belize Advocacy Movement; Centro de Orientacin e Investigacin Integral in partnership with Jvenes de la Vida Real (Dominican Republic); GrenCHAP Inc. (Grenada); two unnamed organizations in Jamaica; United and Strong, Inc. (Saint Lucia); Foundation HE + HIV (Suriname); MSM: No Political Agenda and Friends For Life (Trinidad and Tobago). Friends For Life (Trinidad & Tobago) This project utilizes trained peer educators to increase access to sexual health services (including HIV voluntary counseling and testing) for LGBT individuals, other MSM, and transgender and male sex workers. Central to the project is the distribution of condoms, lubricant, safer sex information, and referral information cards. The project also collects baseline data on HIV/AIDS prevention knowledge among MSM, and provides one-to-one coping and life-skills counseling for gay men, other MSM, transgender individuals, and sex workers. Eastern Europe and Central Asia Nine groups in Eastern Europe and Central Asia received community awards from amfAR's MSM Initiative: We For Civil Equality (Armenia); Center for Information and Counseling on Reproductive Health - Tanadgoma (Georgia); Kyrgyz Indigo (Krgyzstan); The Siberian Alternative Center (Russia); Oryol Regional Public Organization to Fight AIDS, Phoenix PLUS (Russia); Non-Governmental Organization Safe Pulse of Youth (Serbia); Civil Society Organization Equal Opportunities (Tajikistan); Nikolaev Regional Public Youth Movement Penitentiary Initiative and NGO Insight (Ukraine). The Siberian Alternative Center NGO (Russia) Building upon a previous amfAR award, this project engages female friends of gay men, other MSM, and transgender individuals as counselors and educators. Taking advantage of the special relationship that exists between MSM/transgender individuals and their female friends, through training and regular meetings these women will assist in providing effective behavior change communication to reduce risky sexual behavior among MSM/TG. Latin America Seven organizations in Latin America received community awards: VIVO POSITIVO (Chile); Fundacin Radio Diversia (Colombia); Asociacin Jvenes en Movimiento (Honduras); SOMOSGAY (Paraguay); VA LIBRE in partnership with Asociacin Amigos por Siempre Promoviendo Tus Derechos AAxS (Peru); Instituto de Estudios en Salud, Sexualidad y Desarrollo Humano (Peru); Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela). Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela) This direct service intervention aims to empower young gay Yukpa men through skills-building workshops, discussion groups, and the development of a culturally appropriate HIV prevention and life skills handbook. Global Advocacy Corps Awards The Global Advocacy Corps is a small grants program shared by the Public Policy and MSM Initiative programs of amfAR. The advocacy work funded through this program emphasizes the use of new evidence and tools, and more strategic approaches to tackling the epidemic on a national level. It supports development of analyses and other writing, as well as follow-through advocacy with government, donors, and communities. A central goal of the awards is to affect national and donor policy: to make national responses to HIV/AIDS better funded, more strategic, more ambitious in terms of public health impact, and more focused on outcomes for individuals and communities affected by HIV/AIDS. It is expected that grantees draw on the latest research to make the case for new and smarter investments to improve HIV-related results. Two Global Advocacy Corps awards totaling $40,000 were made to groups in Kenya and Namibia in 2011. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among MSM and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and MSM. In 2011, the MSM Initiative staff worked with the Policy team and colleagues at Johns Hopkins University to compile and edit an MSM global report-titled "Achieving an AIDS-Free Generation for Gay Men and Other MSM"-which finds that resources dedicated to addressing the epidemic among MSM are grossly insufficient, and that funding intended for this population is often diverted away from MSM-related services. The report was released in 2012. Program Service Accomplishments (6) Part III, Line 4a-4d (6) public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill AIDS Summit Spearheaded by Senior Medical and Policy Advisor Susan Blumenthal, amfAR brought together many of the biggest names in HIV research, policy, and advocacy for a half-day conference that filled the Senate Kennedy Caucus Room to capacity. Speakers and panelists included Dr. Anthony Fauci of the National Institutes of Health; Melody Barnes, director of the White House Domestic Policy Council; Dr. Michel Kazatchkine, executive director of the Global Fund; and Dr. Margaret Hamburg, commissioner of the FDA. Speakers discussed ideas and strategies for halting the epidemic, and Whoopi Goldberg, Cokie Roberts, and Chris Matthews lent their star power to help focus the day's message: ending the AIDS epidemic. House Democratic Leader Nancy Pelosi (D-CA), along with Reps Barbara Lee (D-CA), Henry Waxman (D-CA), Nita Lowey (D-NY), and Jim Himes (D-CT), as well as Senators Kirsten Gillibrand (D-NY) and Mike Enzi (R-WY) all made appearances to strongly voice their continued support for amfAR and the fight against AIDS. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving programs. In December 2009, the Foundation celebrated a major victory on this front when Congress lifted the ban on federal funding for syringe exchange programs (SEPs). However, in anticipation of a House proposal to reinstate the ban on federal funds for syringe access, amfAR's public policy office worked throughout1 2011with Senate Foreign Operations and Financial Services staff and Senator Sherrod Brown's office on this issue. amfAR staff made a presentation on US drug policy and organized a meeting of PEPFAR intravenous drug users (IDU) implementers at the Beirut Harm Reduction Conference. And in March, the policy team organized and attended meetings with staff to key Senators and House Minority Leader Pelosi. Also in March, amfAR staff hosted a strategy meeting in Congress on syringe exchange. amfAR funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 20 authorized SEPs statewide, which have served more than 155,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the ongoing epidemic in the U.S., where more than one million people are living with the virus. In 2011, public policy staff members attended a U.S. Department of Health & Human Services (HHS) meeting on redesigning reporting requirements for federal grant recipients so they are aligned with the national strategy, which was unveiled by the White House in July 2010 and emerged with help from the HIV/AIDS advocacy community. amfAR staff also spearheaded a sign-on statement-signed by more than 140 organizations-supporting the national strategy and laying out several principles for its success, including calls for expanded services and protection of Medicaid expansion and health reform. Public policy staff were also featured in a White House video on the first anniversary of the national strategy. Global Health In 2011, public policy staff worked with fellow AIDS advocates to argue against funding cuts for global HIV/AIDS initiatives, including the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria, and focused on the need to scale up HIV prevention efforts, both domestically and globally, as an effective way to combat the worldwide AIDS epidemic. In addition to meeting with key administration officials and members of Congress, amfAR released a series of publications arguing against the case for cutting global AIDS funding. In July 2011, the Foundation released two new issue briefs: "Ending the HIV/AIDS Epidemic" drew on the latest research to make the case that with strategic investments we can make great strides against the epidemic; "FY12 Global Health Funding Proposals: Projecting the Human Impact" estimated the human impact of various budget scenarios. In February, the public policy office released a report showing the potential human impact of global health funding cuts as proposed in September 2010 by House Minority Leader John Boehner. Vertical Transmission Preventing hundreds of thousands of HIV-positive mothers from passing the virus to their children "is one of the startling successes in the response to the global AIDS epidemic," said amfAR Vice President and Director of Public Policy Chris Collins in his opening remarks at an amfAR-sponsored Capitol Hill briefing on January 31. Recognizing these extraordinary gains-and the imperative of extending these gains further-a panel of experts at the Washington, D.C., briefing highlighted the challenges to fully eradicating mother-to-child HIV transmission The briefing brought together experts from the U.S. government, foundations, and NGOs that sponsor prevention of mother-to-child transmission (PMTCT) services. MSM amfAR's policy office works closely with the MSM Initiative to advocate expanded access to HIV prevention and treatment services for MSM worldwide, and to fight the stigma and discrimination that make MSM more vulnerable to HIV infection and inhibit equal access to care. Working with Trust for America's Health, amfAR released an issue brief proposing "A New HIV Prevention Paradigm for Gay and Bisexual Men in the U.S.," emphasizing efforts to address the context of risk, including expanded HIV treatment access to reduce community viral load, and anti-discrimination, anti-stigma, and anti-bullying efforts. Policy staff also co-sponsored, with Advocates for Youth, a community forum on Sexual Rights and HIV Prevention in Nigeria featuring activist Stephen Chukwumah and presented at a COC Netherlands conference in Moldova on opportunities for funding and policy change for LGBT groups in the region. When Ugandan MSM advocate David Kato was brutally murdered in January, amfAR put out a release calling for an independent investigation and policy staff utilized social media to call on the US State Department to press the Ugandan government to fully investigate the murder. A "Prevention Revolution" Advocating increased funding for lifesaving HIV/AIDS research is another of amfAR's policy priorities. In March 2011, amfAR sponsored a Capitol Hill briefing-titled "Accelerating an HIV Prevention Revolution: A Roadmap"-that was attended by more than a dozen leading government, research, policy, and medical experts. Citing major advances during the past year in pre-exposure prophylaxis (PrEP) and microbicide trials, strides in vaccine research, the use of social media, and treatment as a means of preventing viral transmission, the speakers-including high-level representatives from the Centers for Disease Control and Prevention (CDC), UNAIDS, the National Institutes of Health (NIH), and the San Francisco Department of Public Health-stressed that, 30 years into the epidemic, the world finds itself in a new era of prevention. Many of the speakers touched on the global application of new HIV prevention techniques, and underscored the importance of further study and funding for these initiatives. Pre-Exposure Prophylaxis Pre-exposure prophylaxis (PrEP)-which involves giving antiretroviral therapy to HIV-negative people at high risk of becoming infected-holds great promise as a potential prevention intervention. In 2011, amfAR, as part of a coalition of partners, organized and participated in calls, meetings, and forums while continuing to encourage regulatory approval of PrEP for MSM domestically. Policies Form 990, Part VI, Section B Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. Disclosure Form 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. Functional Expenses Part IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. Other Changes in Net Assets FORM 990, SECTION XI, LINE 5 UNREALIZED LOSS.............(465,956) OTHER CHANGES................135,728 ------------ TOTAL LINE 5 (330,228) ============